Com­pli­an­ce with the IVDR now! The IVDR takes effect as of 26 May 2022: keep in mind tran­si­tio­nal periods!

Regu­la­ti­on (EU) 2017/746 on in-vitro dia­gnostics (the IVDR) has been in effect sin­ce 26 May 2022, repla­cing Direc­ti­ve 98/79/EC on in-vitro dia­gnostics (the IVDD). As of this date, in-vitro dia­gnostics are requi­red to com­ply with the IVDR. For a lar­ge num­ber of in-vitro dia­gnostics, this means the inclu­si­on of a noti­fied body in the con­for­mi­ty assess­ment pro­ce­du­re (link to the Janu­a­ry news­let­ter: “Grace Peri­od for IVDR Com­pli­an­ce”). Given the small num­ber of noti­fied bodies which have been accredi­ted in accordance with the IVDR, the inclu­si­on of noti­fied bodies poses a chal­len­ge for manu­fac­tu­rers of in-vitro dia­gnostics. This cir­cum­s­tance has been unders­tood by Euro­pean law­ma­kers after hea­ring clear messages from the indus­try, and manu­fac­tu­rers of in-vitro dia­gnostics who­se con­for­mi­ty assess­ment pro­ce­du­res are to inclu­de a noti­fied body in accordance with the IVDR have been gran­ted exten­ded tran­si­tio­nal peri­ods for com­pli­an­ce with the IVDR.

Tran­si­tio­nal peri­ods for com­pli­an­ce with the IVDR based on the risk class of the in-vitro diagnostics

The length of the­se tran­si­tio­nal peri­ods depends on the risk class of the in-vitro dia­gnostics. Manu­fac­tu­rers of in-vitro dia­gnostics can only bene­fit from the­se tran­si­tio­nal peri­ods if their pro­ducts meet the spe­ci­fi­ca­ti­ons of the IVDD and if no signi­fi­cant chan­ges are made after 26 May 2022 to the device its­elf or to its inten­ded purpose.

Expi­ra­ti­on of the tran­si­tio­nal peri­ods will mean that in-vitro dia­gnostics will be requi­red to com­ply in full with the IVDR as of the fol­lowing dates:

  • For Class A in-vitro dia­gnostics (non-sterile) and in-vitro dia­gnostics of all clas­ses who­se decla­ra­ti­on of con­for­mi­ty is issued after 26 May 2022, the effec­ti­ve date for com­pli­an­ce with the IVDR is 26 May 2022.
  • For Class D in-vitro dia­gnostics, the effec­ti­ve date for com­pli­an­ce with the IVDR is 26 May 2025, pro­vi­ded their decla­ra­ti­on of con­for­mi­ty was issued pri­or to 26 May 2022.
  • For Class C  in-vitro dia­gnostics, the effec­ti­ve date for com­pli­an­ce with the IVDR is 26 May 2026, pro­vi­ded their decla­ra­ti­on of con­for­mi­ty was issued pri­or to 26 May 2022.
  • For Class B and Class A (ste­ri­le) in-vitro dia­gnostics, the effec­ti­ve date for com­pli­an­ce with the IVDR is 26 May 2027, pro­vi­ded their decla­ra­ti­on of con­for­mi­ty was issued pri­or to 26 May 2022.

In-vitro dia­gnostics which are pla­ced on the mar­ket pri­or to their effec­ti­ve date for com­pli­an­ce with the IVDR may be made avail­ab­le on the mar­ket for one addi­tio­nal year after the pas­sa­ge of their effec­ti­ve date (the “sell-off rule”), with “making avail­ab­le on the mar­ket” defi­ned as any sup­ply of a device for dis­tri­bu­ti­on, con­sump­ti­on or use on the Uni­on mar­ket in the cour­se of a com­mer­cial acti­vi­ty, whe­ther in return for pay­ment or free of char­ge. This means e.g. that devices which are pla­ced on the mar­ket, i.e. which were made avail­ab­le in the Uni­on mar­ket for the first time, pri­or to the device’s effec­ti­ve date for com­pli­an­ce with the IVDR may con­ti­nue to be sold for one addi­tio­nal year after the effec­ti­ve date specified.

Manu­fac­tu­rers of in-vitro dia­gnostics which are pla­ced on the mar­ket after their effec­ti­ve date for com­pli­an­ce with the IVDR are requi­red to ensu­re that their devices meet the requi­re­ments of the IVDR. Other­wi­se, manu­fac­tu­rers face the thre­at of mea­su­res by the mar­ket sur­veil­lan­ce aut­ho­ri­ties, which may inclu­de orders pro­hi­bi­t­ing them from making their devices avail­ab­le on the mar­ket, as well as recall or with­dra­wal orders. For manu­fac­tu­rers of Class A (non-sterile) in-vitro dia­gnostics and in-vitro dia­gnostics of all clas­ses who­se decla­ra­ti­on of con­for­mi­ty is issued after 26 May 2022, mar­ket sur­veil­lan­ce mea­su­res may be adop­ted right now.

The tran­si­tio­nal peri­ods do not affect all requi­re­ments for manufacturers

Some pro­vi­si­ons of the IVDR take effect on 26 May 2022 for all in-vitro dia­gnostics, regard­less of risk class. From that date for­ward, manu­fac­tu­rers will be requi­red to adhe­re to the fol­lowing pro­vi­si­ons of the IVDR:

  • the requi­re­ments for post-market sur­veil­lan­ce of their devices through imple­men­ta­ti­on of a sur­veil­lan­ce sys­tem and repor­ting on the sur­veil­lan­ce and safe­ty of their devices;
  • the requi­re­ments con­cer­ning vigi­lan­ce with regard to serious inci­dents and field safe­ty cor­rec­ti­ve actions;
  • the requi­re­ments for regis­tra­ti­on of eco­no­mic ope­ra­tors and devices in Eudamed.

In this case as well, vio­la­tors face the thre­at of seve­re mea­su­res by the mar­ket sur­veil­lan­ce aut­ho­ri­ties, inclu­ding pos­si­ble recall or with­dra­wal orders.

Sum­ma­ry

If they have not alrea­dy done so, manu­fac­tu­rers should immedia­te­ly com­ply with the IVDR’s requi­re­ments for the regis­tra­ti­on of devices and of the manu­fac­tu­rers them­sel­ves, as well as tho­se rela­ting to post-market sur­veil­lan­ce of their devices and vigi­lan­ce requi­re­ments, in order to avoid mea­su­res by the mar­ket sur­veil­lan­ce authorities.

Regard­less of the risk class of their devices, manu­fac­tu­rers are advi­sed to imple­ment the IDVR’s requi­re­ments in a time­ly man­ner and in par­ti­cu­lar to expe­di­te the con­for­mi­ty assess­ment pro­ce­du­re with invol­ve­ment of the noti­fied body. This pro­ce­du­re may take a con­si­derable amount of time given the small num­ber of accredi­ted noti­fied bodies, and manu­fac­tu­rers should take this into account in plan­ning for the date on which they will be requi­red to com­ply in full with the IVDR.

back

Stay up-to-date

We use your e-mail address exclusively for sending our newsletter. You have the right to revoke your consent at any time with effect for the future. For further information, please refer to our privacy policy.